Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information

Note 10 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO, as Chief Operating Decision Maker, assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three months ended March 31, 2026 and 2025 (amounts in thousands):

 

    March 31, 2026     March 31, 2025  
    For the three months ended  
    March 31, 2026     March 31, 2025  
Net revenues                
Diagnostic services   $ -     $ -  
Consumer products     478       1,431  
Consolidated net revenue     478       1,431  
Cost of revenue                
Diagnostic services     -       232  
Consumer products     311       673  
Consolidated cost of revenue     311       905  
Depreciation and amortization expense                
Diagnostic services     -       334  
Consumer products     623       807  
Total Depreciation and amortization expense     623       1,141  
Operating and other expenses                
Diagnostic services     -       168  
Consumer products     562       1,061  
Unallocated corporate     2,962       2,834  
Total  operating and other expenses     3,524       4,063  
Income (loss) from operations, before income taxes                
Diagnostic services     -       (734 )
Consumer products     (1,018 )     (1,110 )
Unallocated corporate     (2,962 )     (2,834 )
Total loss from operations, before income taxes     (3,980 )     (4,678 )
Income tax expense     (1,374 )      -  
Total loss from operations, after income taxes     (5,354 )     (4,678 )
Net loss from continuing operations   $ (5,354 )   $ (4,678 )

 

The following table is a summary of segment information as of March 31, 2026 and December 31, 2025 (amounts in thousands):

 

    March 31, 2026     December 31, 2025  
ASSETS                
Consumer products   $ 10,973     $ 11,614  
Unallocated corporate     47,757       48,257  
Total assets   $ 58,730     $ 59,871